Table 2 Univariable logistic analysis of risk for hospital-acquired VTE

Female

2.294

1.671–3.149

 < 0.001

Age

1.065

1.049–1.081

 < 0.001

BMI

0.974

0.928–1.022

0.282

D-Dimer

1.192

1.148–1.238

 < 0.001

NYHA FC

2.574

2.136–3.101

 < 0.001

Prior venous thromboembolism

7.334

3.828–14.049

 < 0.001

Hypertension

0.941

0.801–1.106

0.460

Infection

7.457

5.292–10.506

 < 0.001

Renal insufficiency

6.116

4.161–8.990

 < 0.001

Pulmonary hypertension

11.248

7.881–16.052

 < 0.001

Obstructive sleep apnea

2.275

1.457–3.552

 < 0.001

Stroke

1.243

0.750–2.061

0.399

Valvular heart disease

5.851

4.243–8.068

 < 0.001

Chronic coronary syndrome

0.528

0.369–0.755

 < 0.001

Acute coronary syndrome

1.682

1.101–2.568

0.016

Cardiomyopathy

4.295

2.969–6.214

 < 0.001

Respiratory failure

18.037

9.511–34.209

 < 0.001

Hyperhomocysteinemia

1.194

0.489–2.921

0.697

Rheumatic disease

1.506

0.209–10.852

0.684

Diabetes

1.186

0.850–1.655

0.316

Heart failure

6.061

4.389–8.369

 < 0.001

Malignant tumor

2.383

0.972–5.844

0.058

Hepatic insufficiency

3.238

2.144–4.891

 < 0.001

Immobility

47.593

24.754–91.506

 < 0.001

Atrial fibrillation

1.888

1.329–2.682

 < 0.001

Mechanical ventilation

3.227

1.782–5.846

 < 0.001

Central venous catheterization

17.600

9.934–31.181

 < 0.001

IABP

20.826

10.619–40.844

 < 0.001

Steroids

1.363

0.433–4.293

0.597

Anticoagulation

0.495

0.350–0.700

 < 0.001

Antiplatelet

0.450

0.327–0.620

 < 0.001

Statin

0.618

0.441–0.867

0.005

Padua Score (continuous)

2.103

1.922–2.301

 < 0.001

Padua Score (category)

12.362

7.969–19.176

 < 0.001